Formulation: A crystalline solid
Formal Name: N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-alaninamide
Purity: ≥95%
Formula Markup: C26H27F4N3O7
Formula Weight: 569,5
Shelf life (days): 1460
CAS Number: 254750-02-2
Notes: Emricasan is a pan-caspase inhibitor.{42093,42094,42095,42096} Ex vivo, emricasan (10 mg/kg) prevents cold ischemia-warm reperfusion-induced sinusoidal endothelial cell (SEC) apoptosis and inhibits caspase-3 activation in rat liver by 55 and 94%, respectively.{42093} In vivo, emricasan reduces alanine aminotransferase (ALT) levels (ED50s = <0.01-0.38 mg/kg) as well as apoptosis and caspase activity in a dose-dependent manner in the α-Fas mouse and D-Gln/LPS rat models of liver injury.{42094} Emricasan reduces caspase-3 and caspase-8 activity, serum ALT levels, hepatocyte apoptosis, and hepatic fibrogenesis in a mouse model of high-fat diet-induced non-alcoholic steatohepatitis (NASH).{42095} It also enhances islet engraftment and lowers post-transplant fasting glucose levels in a porcine islet autotransplant model.{42096}
English
Deutsch
